Study of extra treatment for ultra-low rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if adding an immunotherapy drug (tislelizumab) to standard chemoradiation and chemotherapy helps patients with ultra-low rectal cancer. It is for patients whose cancer has not spread and can be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have a type of rectal cancer called adenocarcinoma that is confirmed by a biopsy.
- Your tumor must be within about 1.2 inches from the anal opening.
- You must not have had any prior treatment for rectal cancer.
- Your cancer must be at a stage where it can be removed by surgery, and not have spread to other parts of the body.
- You must be in generally good health (able to do daily activities without help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug tislelizumab with standard chemotherapy and radiation before surgery to see if it can help patients with low rectal cancer avoid surgery or keep their organs. It is for people whose tumors are close to the anus and have not spread.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial is testing a combination of immunotherapy (PD-1 antibody) with a targeted biologic (IL-2) and chemotherapy (CapeOX) to shrink advanced rectal cancers located very low in the rectum. The goal is to avoid surgery and preserve the rectum and its function.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests adding an immunotherapy drug (QL1706) to standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to see if this combination can shrink tumors more effectively.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.